MKSI Stock Analysis: MKS Instruments | NASDAQ
Scientific & Technical Instruments | NASDAQ, USA | Market Cap: 17.294m USD | 12M Return: 157% | US55306N1046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 331M
EPS Trend: 96.4%
Qual. Beats: 2
Rev. Trend: 71.6%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MKS Inc. supplies foundational technology solutions to semiconductor manufacturing, electronics and packaging, and specialty industrial markets, operating through three segments: Vacuum Solutions (VSD), Photonics Solutions (PSD), and Material Solutions (MSD). The VSD segment delivers pressure, flow, gas delivery, and gas analysis technologies; PSD offers lasers, photonics, optics, and precision motion control; and MSD provides surface modification, plating, and finishing technologies for chemistry, equipment, and high-technology applications. The company sells through direct sales, independent distributors, sales representatives, and online product catalogs, serving customers primarily in the United States, China, South Korea, Japan, Taiwan, and Singapore.
The firm is classified within the Semiconductor Materials & Equipment sub-industry, a sector that supplies critical subsystems, components, and consumables integrated into wafer fabrication and packaging lines operated by semiconductor manufacturers and OEMs. Originally incorporated in 1961 and headquartered in Andover, Massachusetts, the company was renamed MKS Inc. in May 2025, having previously operated as MKS Instruments, Inc.
- Semiconductor equipment demand rebound lifts Vacuum Solutions revenue
- Atotech integration progresses; MSD margin expansion remains key catalyst
- China revenue exposure heightens geopolitical risk amid export controls
| Net Income: 440.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.50 > 1.0 |
| NWC/Revenue: 8.05% < 20% (prev 44.18%; Δ -36.13% < -1%) |
| CFO/TA 0.07 > 3% & CFO 635.0m > Net Income 440.0m |
| Net Debt (3.82b) to EBITDA (1.06b): 3.60 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (72.7m) vs 12m ago 7.86% < -2% |
| Gross Margin: 44.12% > 18% (prev 47.34%; Δ -3.22% > 0.5%) |
| Asset Turnover: 48.93% > 50% (prev 42.36%; Δ 6.57% > 0%) |
| Interest Coverage Ratio: 3.75 > 6 (EBIT TTM 717.0m / Interest Expense TTM 191.0m) |
| A: 0.04 (Total Current Assets 2.77b - Total Current Liabilities 2.42b) / Total Assets 8.94b |
| B: 0.10 (Retained Earnings 936.0m / Total Assets 8.94b) |
| C: 0.08 (EBIT TTM 717.0m / Avg Total Assets 8.88b) |
| D: 0.50 (Book Value of Equity 2.99b / Total Liabilities 5.95b) |
| Altman-Z'' = 1.67 = BB |
| DSRI: 1.10 (Receivables 830.0m/649.0m, Revenue 4.35b/3.74b) |
| GMI: 1.07 (GM 47.34% / 44.12%) |
| AQI: 0.96 (AQ_t 0.57 / AQ_t-1 0.60) |
| SGI: 1.16 (Revenue 4.35b / 3.74b) |
| TATA: -0.02 (NI 440.0m - CFO 635.0m) / TA 8.94b) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of September 07, 2026, the stock is trading at USD 260.31 with a total of 1,630,509 shares traded. Over the past week, the price has changed by +1.78%, over one month by -18.77%, over three months by -21.10% and over the past year by +156.98%.
Current recommended Stop Loss: 228.30 (which is 12.3% or 2.1 ATR below the current price).
MKS Instruments has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy MKSI.
- StrongBuy: 7
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 411.3 | 58% |
P/E Trailing = 40.6614
P/E Forward = 10.3627
P/S = 3.9783
P/B = 6.1324
P/EG = 1.3236
Revenue TTM = 4.35b USD
EBIT TTM = 717.0m USD
EBITDA TTM = 1.06b USD
Long Term Debt = 2.54b USD (from longTermDebt, last quarter)
Short Term Debt = 1.40b USD (from shortTermDebt, last quarter)
Debt = 4.43b USD (from shortLongTermDebtTotal, last quarter) + Leases 243.0m
Net Debt = 3.82b USD (calculated: Debt 4.43b - CCE 611.0m)
Enterprise Value = 21.1b USD (17.3b + Debt 4.43b - CCE 611.0m)
Interest Coverage Ratio = 3.75 (Ebit TTM 717.0m / Interest Expense TTM 191.0m)
EV/FCF = 46.50x (Enterprise Value 21.1b / FCF TTM 454.0m)
FCF Yield = 2.15% (FCF TTM 454.0m / Enterprise Value 21.1b)
FCF Margin = 10.44% (FCF TTM 454.0m / Revenue TTM 4.35b)
Net Margin = 10.12% (Net Income TTM 440.0m / Revenue TTM 4.35b)
Gross Margin = 44.12% ((Revenue TTM 4.35b - Cost of Revenue TTM 2.43b) / Revenue TTM)
Gross Margin QoQ = 47.68% (prev 41.19%)
Tobins Q-Ratio = 2.36 (Enterprise Value 21.1b / Total Assets 8.94b)
Interest Expense / Debt = 4.31% (Interest Expense 191.0m / Debt 4.43b)
Taxrate = 9.84% (48.0m / 488.0m)
NOPAT = 646.5m (EBIT 717.0m * (1 - 9.84%))
Current Ratio = 1.14 (Total Current Assets 2.77b / Total Current Liabilities 2.42b)
Debt / Equity = 1.48 (Debt 4.43b / totalStockholderEquity, last quarter 2.99b)
Debt / EBITDA = 3.60 (Net Debt 3.82b / EBITDA 1.06b)
Debt / FCF = 8.41 (Net Debt 3.82b / FCF TTM 454.0m)
Total Stockholder Equity = 2.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.95% (Net Income 440.0m / Total Assets 8.94b)
RoE = 15.83% (Net Income TTM 440.0m / Total Stockholder Equity 2.78b)
RoCE = 13.47% (EBIT 717.0m / Capital Employed (Equity 2.78b + L.T.Debt 2.54b))
RoIC = 8.40% (NOPAT 646.5m / Invested Capital 7.70b)
WACC = 14.43% (E(17.3b)/V(21.7b) * Re(17.13%) + D(4.43b)/V(21.7b) * Rd(4.31%) * (1-Tc(0.10)))
Discount Rate = 17.13% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 73.51 | Cagr: 3.42%
[DCF] Terminal Value 55.65% ; FCFF base≈469.2m ; Y1≈440.6m ; Y5≈408.2m
[DCF] Fair Price = N/A (negative equity: EV 3.21b - Net Debt 3.82b = -606.1m; debt exceeds intrinsic value)
EPS Correlation: 96.36 | EPS CAGR: 29.60% | SUE: 2.55 | # QB: 2
Revenue Correlation: 71.59 | Revenue CAGR: 4.94% | SUE: 3.90 | # QB: 2
EPS current Quarter (2026-09-30): EPS=3.62 | Chg30d=+14.75% | Revisions=+79% | Analysts=13
EPS current Year (2026-12-31): EPS=13.13 | Chg30d=+12.09% | Revisions=+79% | GrowthEPS=+66.7% | GrowthRev=+29.2%
EPS next Year (2027-12-31): EPS=17.61 | Chg30d=+14.63% | Revisions=+77% | GrowthEPS=+34.1% | GrowthRev=+20.5%
[Analyst] Revisions Ratio: +91% (up=32, down=0)